The current study expands the application of pharmacologic MC4R stimulation by demonstrating that the MIA mouse model of autism is responsive to MT-II treatment, suggesting a promising approach for further clinical investigation regarding individuals with in utero exposure to infection. This evidence concerns the gene MC4R and infection.